« Back
Home /
Bosentan (hydrate)

Bosentan (hydrate)

Item no.	HY-A0013A-50mg
Manufacturer	MedChem Express
CASRN	157212-55-0
Amount	50 mg
Quantity options	100 mg 10mM/1mL 1 g 200 mg 500 mg 50 mg 5 g
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.93
Formula	C27H31N5O7S
Citations	J Exp Clin Cancer Res. 2025 Feb 21;44(1):64. Acta Pharmacol Sin. 2022 Nov 30. Am J Physiol Endocrinol Metab. 2019 Sep 1;317(3):E548-E558. Am J Physiol Heart Circ Physiol. 2019 Nov 1;317(5):H1166-H1172. Biopharm Drug Dispos. 2022 Oct 4. bioRxiv. 2023 Apr 22. Biotechnol Bioeng. 2021 Sep 3. BMC Cancer. 2018 Feb 6;18(1):154. Cell Biol Toxicol. 2021 Jan 20. Cell Death Dis. 2024 May 22;15(5):358. Cells. 2021, 10(11), 3072. Chem Res Toxicol. 2025 Feb 3. Clin Immunol. 2023 Jul 5;109687. Curr Issues Mol Biol. 2023, 45(1), 555-570. Department of Physiology and Pathophysiology. 2020 Sep. Hypertension. 2019 Dec;74(6):1409-1419. J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Feb 1:1252:124443. J Toxicol Sci. 2024;49(8):337-348. Microcirculation. 2021 Aug 5;e12724. Patent. US20220288064A1. Patent. US20220317132A1. Phytomedicine. 2019 Mar 15;56:175-182. Phytomedicine. 2023 Sep 2, 155054. PLoS One. 2016 Dec 28;11(12):e0167713. Sci Rep. 2022 Sep 28;12(1):16156. Toxicology. 2020 May 15;437:152445. [1]Dhillon S, et al. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2009;9(5):331-50. [2]Akamata K, et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther. 2014 Apr 3;16(2):R86. [3]Iglarz M, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014 Nov 24;118(2):333-9.
Smiles	O=S(NC1=NC(C2=NC=CC=N2)=NC(OCCO)=C1OC3=CC=CC=C3OC)(C4=CC=C(C(C)(C)C)C=C4)=O.O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	157212-55-0
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Endothelin Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	569.63
Product Description	Bosentan hydrate is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors with Ki of 4.7 nM and 95 nM in human SMC, respectively.
Manufacturer - Research Area	Cardiovascular Disease; Endocrinology; Cancer
Solubility	DMSO : ≥ 100 mg/mL\|Ethanol : 50 mg/mL (ultrasonic)\|H2O : < 0.1 mg/mL
Manufacturer - Pathway	GPCR/G Protein
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-A0013A-50mg-safety-datasheet.pdf